ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain [Seeking Alpha]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Seeking Alpha
IBRX faces formidable competition from JNJ's Inlexzo, which demonstrates superior efficacy and commercial advantages, threatening Anktiva's long-term market share. Despite strong initial revenue growth, IBRX's high cash burn, heavy dilution risk, and elevated valuation multiples make the stock unattractive at current levels. I rate IBRX stock a cautious Sell, citing single-product risk, competitive headwinds, and likely further dilution absent rapid pipeline expansion. FatCamera/E+ via Getty Images Last week, ImmunityBio, Inc. ( IBRX ) provided news that its lead drug candidate Anktiva – an oncology treatment – received a conditional marketing authorization recommendation from the European Medicines Agency when used with This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expres
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (NASDAQ:IBRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder CancerBusiness Wire
- Should EMA's Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 3
- 12/15/25 - Form 8-K
- IBRX's page on the SEC website